| General peripheral tolerance | Ref |
| T cell negative selection in thymus | [6] | Natural (thymic) Tregs | [7, 8] | Acquired (adaptive) Tregs | [9, 10] | Local immunosuppression (IDO, TGF-β, IL10, CTLA-4) | [11–27] |
| CNS-specific privilege | Ref |
| Reduced lymphatic transport to draining lymph nodes | [28–33] | Lack of resident immunogenic APCs (dendritic cells) | [28, 29, 34–37] | Specialized endothelium excludes naïve T cells | [28, 29, 34, 35, 38] | Local immunosuppression by astrocytes and microglia | [28, 35, 38–41] |
| Tumor-induced immunosuppression (CNS and non-CNS) | Ref |
| Local activation of natural Tregs | [7, 42–44] | Tumor-specific (adaptive) Tregs | [42, 44–48] | Local intratumoral immunosuppression | | IDO | [16, 45, 47–53] | Arginase | [42, 54, 55] | TGF-β | [56–59] | IL10 | [60, 61] | CTLA-4 | [11, 62–65] | PD-L1 | [11, 46, 62, 66] | Myeloid-derived suppressor cells | [67–70] | Tolerogenic APCs | [42, 44, 45, 47, 48, 61, 71–73] | Tolerogenic draining lymph nodes | [45, 47, 48, 73] | Quiescent vascular endothelium | [74–79] |
|
|